• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    111.13 +0.91 (+0.83%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Ligand Pharm

    < Previous 1 2 3 Next >
    Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
    Via Benzinga
    Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
    Via Benzinga
    The Latest Analyst Ratings For Ligand Pharmaceuticals
    Via Benzinga
    Looking Into Ligand Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
    After Monday's panicked global sell-off, markets have calmed down. 
    Via Investor's Business Daily
    Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
    Via Benzinga
    Ligand Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
    Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
    Via Investor's Business Daily
    3 Magnificent Growth Stocks to Buy Hand Over Fist
    Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
    Via The Motley Fool
    Topics Economy
    Exposures Interest Rates
    3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
    With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
    Via InvestorPlace
    LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
    While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... 
    Via Talk Markets
    Where Ligand Pharmaceuticals Stands With Analysts
    Via Benzinga
    Analyst Expectations for Ligand Pharmaceuticals's Future
    Via Benzinga
    Recap: Ligand Pharmaceuticals Q1 Earnings
    Via Benzinga
    7 Small-Cap Stocks for the Thinking Speculator
    While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. 
    Via InvestorPlace
    Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
    Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. 
    Via Benzinga
    Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
    Via Benzinga
    Ligand Pharmaceuticals Earnings Preview
    Via Benzinga
    Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
    Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
    Via Benzinga
    Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... 
    Via Benzinga
    Why Are Novan Shares Nosediving Today?
    Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to  
    Via Benzinga
    3 Stocks That Smart Investors Should Be Flocking to Now
    Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
    Via InvestorPlace
    Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
    Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
    Via Benzinga
    Earnings Scheduled For February 22, 2023
    Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.